Titilola Akintola

Titilola Akintola

Auto-generated profile, based on publicly available information

Titilola Akintola

Department of Pain Translational Symptom Science, School of Nursing, University of Maryland, Baltimore, USA; Center to Advance Chronic Pain Research, University of Maryland, Baltimore, USA; Placebo Beyond Opinions Center, University of Maryland School of Nursing, Baltimore

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2025 in The Journal of Pain
Verified
Journal Article
Open access
NRNandini Raghuraman
Nandini Raghuraman
TATitilola Akintola
Titilola Akintola
FRFenan S. Rassu
Fenan S. Rassu
TOTimothy D. O’COnnor
Timothy D. O’COnnor
SCShuo Chen
Shuo Chen
LCLuana Colloca
Luana Colloca
Socioeconomic Position (SEP) is a multidimensional construct encompassing education, income, occupation, and neighborhood distress, influencing chronic pain severity, interference, and duration. However, its impact on placebo analgesia, where reduced pain perception occurs due to treatment belief, remains understudied. Using a quasi-experimental approach, we investigated SEP's influence on placebo analgesia in 401 participants with temporomandibular disorder (TMD) and 400 pain-free individuals. Using latent class analysis, we grouped participants into two SEP groups based on self-reported education, income, occupation, and neighborhood distress indices, including the area deprivation and distressed community indexes. Ancestry Informative Markers (AIMs) and self-reported race were included to account for genetic and demographic influences. Placebo analgesia was elicited using verbal suggestion and classical conditioning. Linear mixed models were employed to analyze SEP's impact, while multiple regression and ANCOVA assessed AIMs' and race's effects. Comparable placebo effects were observed between participants with TMD and pain-free individuals (F(1,4765.73) = 0.49, p = 0.48). A trend was noted in the main effect of SEP (F(1,4764.5) = 3.64, p = 0.056). Among TMD participants, those with distressed SEP exhibited lower placebo analgesia (F(1,4765.73) = 7.9, p = 0.005), while placebo response did not differ by SEP in pain-free participants (F(1,4765.73) = 0.27, p = 0.59). East Asian ancestry (β = 5.71, 95% CI [1.50, 9.92]) and self-reported Asian (mean = 24.20, sem = 1.52, p = 0.020) were associated with greater placebo analgesia. This study highlights the interplay of SEP, AIMs, and race in placebo analgesia and calls for tailored pain management interventions. PERSPECTIVE: SEP significantly contributes to pain disparities. This quasi-experimental study demonstrates analogous placebo analgesia between chronic pain and pain-free individuals but finds lower placebo analgesia only among individuals with chronic pain and distressed SEP. This highlights a link between chronic pain, SEP, and impaired placebo effects, suggesting new avenues for research.

30 January 2023 in medRxiv
Verified
Preprint
Open access
PDF file
TATitilola Akintola
Titilola Akintola
JCJoyce Chung
Joyce Chung
LALauren Atlas
Lauren Atlas
Introduction The COVID-19 pandemic has been shown to have profound effects on both mental and physical health. Distress and widespread uncertainty about global events and personal risk are associated with increased worry and negative expectations that impact physical health. Thus, the current pandemic poses a possibility for the experience of nocebo effects. Objective To evaluate the likelihood of nocebo-induced COVID-19 symptoms in a US sample. Methods An online study on the mental health impact of COVID-19 asked participants to complete a set of biweekly surveys over a 6-month period between April 2020 and May 2021. We focus on responses from 3,027 individuals who reported never testing positive for COVID-19. We assessed the association between two types of worry and self-reported symptoms of COVID-19. We used multi-level models to examine variations across and within participants over time. We further investigated the effects of pre-existing health conditions and mental health status. Results There was a positive association between symptoms and both general (b= 2.56, p<0.01) and personal worry (b=2.77, p<0.01). However, worry reported at one timepoint was not specifically associated with symptoms reported two weeks later (p = 0.63, p=0.56). We also found that a greater number of prior clinical comorbidities and greater mental health burden were significant predictors of symptom reporting. Conclusions These results suggest that increased worries during the COVID-19 pandemic were associated with greater symptoms. Further studies investigating worry and symptoms in populations with confirmed negative COVID-19 tests or isolated populations will be needed to isolate the occurrence of true nocebo effects during the pandemic.

4 April 2023 in The Journal of Pain
Verified
Journal Article
Closed access
JPJulie Parsons
Julie Parsons
SBSabrina Barhoum
Sabrina Barhoum
MDMaya Joshi Delity
Maya Joshi Delity
JBJama Brookes
Jama Brookes
TATitilola Akintola
Titilola Akintola
LALauren Atlas
Lauren Atlas

27 October 2026 in The Journal of Pain
Verified
Journal Article
Open access
YWYi Wei
Yi Wei
JSJulie S.P. Storkson
Julie S.P. Storkson
KSKai Sherwood
Kai Sherwood
MDMaya Joshi Delity
Maya Joshi Delity
TATitilola Akintola
Titilola Akintola
LALauren Y. Atlas
Lauren Y. Atlas

17 February 2026 in JMIR Preprints
Verified
Preprint
Open access
TATitilola Akintola
Titilola Akintola
TCTiziano Castagnella
Tiziano Castagnella
ECElisa Carlino
Elisa Carlino
LBLindsey Baldwin
Lindsey Baldwin
LFLuca Fornari
Luca Fornari
LCLuana Colloca
Luana Colloca
BACKGROUND Substance use disorder (SUD) is a chronic, relapsing condition characterized by compulsive substance use and dysregulation in reward and control systems. Although effective pharmacological and psychosocial treatments are available, their impact is often limited by barriers such as stigma, poor adherence, and restricted access to care. Virtual Reality (VR) has emerged as a digital health intervention offering an adjunctive approach by providing immersive, interactive environments that may enhance engagement, simulate real-world triggers, and support therapeutic learning. OBJECTIVE This focus review aimed to map and synthesize the existing evidence for VR-based interventions in SUD treatment. We examine both therapeutic applications across established treatment frameworks and experimental approaches, identify key opportunities for future research and clinical innovation. METHODS We searched electronic databases including PubMed/MEDLINE, Science Direct and MDPI covering 2004 to 2025. Two reviewers independently screened for relevant studies and extracted study characteristics. Studies addressing VR applications for substance use disorders including peer-reviewed articles, randomized controlled trials, protocols and pilot studies published in English were selected. Any discrepancies were resolved through discussion. RESULTS A total of 26 studies or protocols were included in this review. Overall, the studies reviewed are broadly categorized into 6 sub-groups based on the type of the VR intervention and treatment class delivered. The reviewed literature indicates that VR-based cue exposure therapy is associated with reductions in craving and physiological reactivity for nicotine, alcohol, and cannabis use, with more limited and preliminary findings for opioid use disorder. VR relaxation and stress-management environments were linked to decreases in craving, stress, and pain among individuals with opioid and alcohol use disorders. VR-enhanced cognitive-behavioral interventions showed improvements in attention, cognitive flexibility, and emotion regulation. Motivational, social skills, and gamified VR interventions were associated with increased engagement, reduced stigma, enhanced self-efficacy, and improved treatment retention. CONCLUSIONS This focus review contributes to the growing digital health literature by synthesizing current evidence on VR-based interventions for SUDs. The findings suggest that VR may serve as a flexible adjunct to existing treatments, with the potential to address persistent barriers to engagement and access. Further rigorously designed studies are needed to evaluate long-term effectiveness, optimize VR design, and support their integration into routine clinical practice.